■Rika devices are installed in more than 300 CSL Plasma centers to increase plasma supply for patients.

■Rika设备已安装在300多家CSL Plasma中心，以增加对患者的血浆供应。

■It takes 1,200 plasma donations each year to treat an individual with severe hemophilia, just one of many conditions for which plasma-derived therapies are the primary treatment.*

■每年需要1200次血浆捐献，才能治疗一名重度血友病患者，而血浆衍生疗法是针对多种病症的主要治疗方法之一。*

1

1

■Over 300 million people globally live with one of more than 7,000 rare diseases.*

■全球有超过3亿人患有7000多种罕见病中的一种或多种。*

2

2

BOCA RATON, Fla., and LAKEWOOD, Colo. – 18 September 2025 –

佛罗里达州博卡拉顿和科罗拉多州莱克伍德——2025年9月18日——

CSL Plasma and Terumo Blood and Cell Technologies (Terumo BCT) today announced that the Rika™ Plasma Donation System has been deployed in all CSL Plasma centers across the U.S. — a major milestone in donor care, operational efficiency and access to lifesaving plasma-derived therapies for patients.

CSL Plasma 和 Terumo 血液与细胞技术公司 (Terumo BCT) 今天宣布，Rika™ 血浆捐赠系统已在美国所有 CSL Plasma 中心投入使用 —— 这是捐献血浆护理、运营效率以及患者获取挽救生命的血浆衍生疗法方面的一个重要里程碑。

“This achievement underscores our commitment to innovation that directly benefits both donors and patients,” said Steve Marlow, general manager and senior vice president at CSL Plasma. “By integrating the Rika system into our operations, we've improved efficiency and the donor experience. Every day, our donors ‘Do the Amazing’ by donating plasma to help those in crucial need of therapies made from plasma.”.

“这一成就彰显了我们对创新的承诺，这些创新直接惠及捐赠者和患者，”CSL Plasma总经理兼高级副总裁史蒂夫·马洛表示。“通过将Rika系统整合到我们的运营中，我们提高了效率并改善了捐赠者的体验。每天，我们的捐赠者通过捐赠血浆来‘成就非凡’，帮助那些迫切需要血浆疗法的人。”

Over the past 18 months, Rika systems have been installed in more than 300 CSL Plasma centers. Developed by Terumo BCT, Rika is a next-generation plasma collection platform designed to enhance the donor experience with faster procedures, improved comfort and enhanced collection personalized for each donor..

在过去的18个月里，Rika系统已经安装在300多家CSL Plasma中心。Rika是由Terumo BCT开发的下一代血浆采集平台，旨在通过更快的流程、更高的舒适度以及为每位献血者量身定制的增强型采集功能来改善献血体验。

The system’s advanced automation, including the iNomi™ Nomogram, tailors collection based on each donor’s hematocrit, weight and height — with an ability of collecting up to 1,000 mL of plasma from eligible donors in less than 35 minutes. With less than 200 mL of blood volume outside the body at any time during the procedure, the system supports enhanced donor comfort and the option to return blood and plasma if a procedure is not completed..

该系统的先进自动化技术，包括 iNomi™ 诺模图，能够根据每位献血者的血细胞比容、体重和身高定制采集过程——可在不到 35 分钟内从符合条件的献血者中采集多达 1,000 毫升的血浆。在操作过程中的任何时候，体外血液量均少于 200 毫升，该系统有助于提升献血者的舒适度，并在操作未完成时提供回输血液和血浆的选项。

“Rika is transforming plasma donation with individualized care and automation that improves efficiency and comfort,” said Patrick Daly, chief business officer at Terumo Blood and Cell Technologies. “Our partnership with CSL Plasma brings this innovation to scale — making it more comfortable for people to donate and expanding access to critical therapies.”.

“Rika正在通过个性化护理和自动化技术革新血浆捐赠，提高效率和舒适度，”泰尔茂血液和细胞技术公司的首席商务官帕特里克·戴利说道。“我们与CSL Plasma的合作使得这一创新得以规模化——使人们捐赠更加舒适，并扩大了对关键疗法的获取途径。”

The Rika system enables a higher yield of plasma donations and reduces time on the donation bed. This allows CSL’s donation centers to collect more efficiently. The increased supply of plasma benefits patients who rely on plasma-derived therapies. These include people with rare and serious conditions — such as immune or bleeding disorders — as well as those needing treatment during childbirth or for burns and trauma in emergency settings..

Rika系统能够提高血浆捐献的产量，并减少捐献床上的时间。这使得CSL的捐赠中心能够更高效地进行采集。血浆供应的增加使依赖血浆衍生疗法的患者受益。其中包括患有罕见和严重疾病的人群——例如免疫或出血性疾病患者——以及那些在分娩期间或在紧急情况下因烧伤和创伤需要治疗的人。

“Thanks to plasma donors, I’ve been able to live a full life — raising my family, enjoying my grandchildren and staying active well into my seventies. Innovations like Rika make donating faster and more comfortable, which means more people like me can keep living the lives we love,” said Pete Atherton, PhD, who relies on plasma-derived medicine..

“感谢血浆捐赠者，我得以过上充实的生活——养育我的家庭，享受与孙辈的时光，并且在七十几岁依然保持活跃。像Rika这样的创新技术让捐赠变得更快速、更舒适，这意味着更多像我这样的人可以继续过着我们热爱的生活，” 依赖血浆衍生药物的皮特·阿瑟顿博士说道。

It is estimated that there are 300 million people globally who live with one of more than 7,000 rare diseases. This highlights the criticality of getting more plasma from each plasma donation. It takes 1,200 plasma donations each year to treat an individual with severe hemophilia, and that is just one of many conditions for which plasma-derived therapies are the primary method of treatment.

据估计，全球有3亿人患有7000多种罕见病中的一种。这凸显了每次血浆捐赠获取更多血浆的关键性。每年需要1200次血浆捐赠才能治疗一名严重血友病患者，而血浆衍生疗法是许多类似疾病的主要治疗方法之一。

As the number of individuals diagnosed with these rare conditions increases, more donations are needed to meet demand..

随着被诊断出患有这些罕见疾病的人数增加，需要更多的捐赠来满足需求。

The nationwide rollout, completed in June, demonstrates a commitment to deploying advanced technology that elevates the donor experience and meets the global demand for plasma-derived medicines.

全国范围的推广于六月完成，展示了对部署先进技术和提升捐赠者体验的承诺，同时满足了全球对血浆衍生药物的需求。

*1

*1

https://www.pptaglobal.org/donate

https://www.pptaglobal.org/donate

*2 World Health Organization. Seventy-eighth World Health Assembly – daily update: 24 May 2025. First-ever rare diseases resolution underscores equity and inclusion. Accessed September 5, 2025.

*2 世界卫生组织。第七十八届世界卫生大会——每日更新：2025年5月24日。首个罕见病决议强调公平与包容。访问日期：2025年9月5日。

https://www.who.int/news/item/24-05-2025-seventy-eighth-world-health-assembly---daily-update--24-may-2025

https://www.who.int/news/item/2025年5月24日-第七十八届世界卫生大会---每日更新-2025年5月24日

.

。

About Plasma

关于 Plasma

Plasma, the liquid component of blood, is rich in proteins, antibodies, clotting factors and essential nutrients. These components play a critical role in treating a variety of medical conditions, including trauma, shock, burns and other emergencies. Plasma-derived therapies are particularly valuable in addressing complex health needs, such as those of women and young mothers during pregnancy and delivery.

血浆是血液的液体成分，富含蛋白质、抗体、凝血因子和必需营养素。这些成分在治疗多种医疗状况中起着关键作用，包括创伤、休克、烧伤和其他紧急情况。血浆衍生疗法在应对复杂健康需求时尤其宝贵，例如女性和年轻母亲在怀孕和分娩期间的需求。

These therapies can also provide lifesaving treatments for a range of chronic and rare conditions, including immune deficiencies, hemophilia, and other bleeding and neurological disorders..

这些疗法还可以为一系列慢性病和罕见病提供挽救生命的治疗，包括免疫缺陷、血友病及其他出血性和神经性障碍。

About CSL Plasma

关于CSL血浆

CSL Plasma

CSL血浆

operates one of the world’s largest and most sophisticated plasma collection networks,with nearly 330 plasma donation centers globally, including in the U.S. and Europe. CSL Plasma is a subsidiary of

运营着全球规模最大、最复杂的血浆采集网络之一，拥有近330个血浆捐赠中心，分布在全球，包括美国和欧洲。CSL Plasma是

CSL

CSL

, a global biopharma company.

，一家全球生物制药公司。

Plasma collected at CSL Plasma facilities is used by CSL for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. This includes people who rely on plasma-derived therapies that treat diseases such as primary immune deficiencies, hereditary angioedema, inherited respiratory disease, hemophilia and other bleeding and neurological disorders..

CSL Plasma设施收集的血浆由CSL用于制造拯救生命的血浆衍生疗法，供应全球100多个国家的患者使用。这些患者依赖血浆衍生疗法来治疗各种疾病，如原发性免疫缺陷、遗传性血管性水肿、遗传性呼吸系统疾病、血友病以及其他出血性和神经性疾病。

The parent company,

母公司，

CSL

CSL

(ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 29,000+ people. For more information about CSL Plasma visit,

总部位于澳大利亚墨尔本的 (ASX:CSL; USOTC:CSLLY) 拥有 29,000 多名员工。有关 CSL Plasma 的更多信息，请访问，

cslplasma.com

cslplasma.com

.

。

About Terumo Blood and Cell Technologies

关于特鲁莫血液和细胞技术

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today.

Terumo Blood and Cell Technologies 是一家医疗技术公司。我们的产品、软件和服务使客户能够收集和制备血液和细胞，以帮助治疗具有挑战性的疾病和病症。我们全球的员工相信血液和细胞有潜力为患者提供比今天更多的帮助。

This belief inspires our innovation and strengthens our collaboration with customers..

这一信念激发了我们的创新，并加强了我们与客户的合作。

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 160 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending..

Terumo血液和细胞技术公司的客户包括血库中心、医院、治疗性单采诊所、细胞采集和处理机构、研究人员以及私人医疗诊所。我们的客户遍布全球160多个国家。我们拥有750多项已授权专利，另有150多项专利正在申请中。

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

我们在美国科罗拉多州莱克伍德设有全球总部，并在全球拥有五个区域总部、八个制造基地和六个创新及研发中心。Terumo Blood and Cell Technologies 是 Terumo Corporation（东京证券交易所代码：4543）的子公司，该公司是全球医疗技术领域的领导者。

To learn more about Terumo Blood and Cell Technologies visit, .

要了解有关 Terumo Blood and Cell Technologies 的更多信息，请访问。

www.TerumoBCT.com

www.TerumoBCT.com

.

。

Rika™ and iNomi™ are either registered trademarks or trademarks of Terumo BCT, Inc in the United States and/or other countries. See

Rika™ 和 iNomi™ 是 Terumo BCT, Inc 在美国和/或其他国家的注册商标或商标。见

TerumoBCT.com/Trademarks

TerumoBCT.com/Trademarks

for details.

详情请见。